Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C

Hepatology

Volumn 54, Issue 5, 2011, Pages 1591-1599

  Liaw, Y F ^a   Jia, J D ^b   Chan, H L Y ^c   Han, K H ^d   Tanwandee, T ^e   Chuang, W L ^f   Tan, D M ^g   Chen, X Y ^h   Gane, E ⁱ   Piratvisuth, T ^j   Chen, L ^k   Xie, Q ^l   Sung, J J Y ^c   Wat, C ^m   Bernaards, C ⁿ   Cui, Y ^o   Marcellin, P ^p  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d Yonsei University   (South Korea)

^e MAHIDOL UNIVERSITY   (Thailand)

^f KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^g CENTRAL SOUTH UNIVERSITY   (China)

^h CAPITAL MEDICAL UNIVERSITY   (China)

ⁱ AUCKLAND CITY HOSPITAL   (New Zealand)

^j PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^k FUDAN UNIVERSITY   (China)

^l SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^m ROCHE PRODUCTS LTD   (United Kingdom)

ⁿ GENENTECH INC   (United States)

^o Shanghai Roche Pharmaceutucals Ltd   (China)

^p CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; PEGINTERFERON ALPHA2A;

ADULT; ALOPECIA; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FACTORIAL DESIGN; FATIGUE; FEMALE; FOLLOW UP; GENOTYPE; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INSOMNIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NONHUMAN; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEROCONVERSION; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

EID: 80055059164     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24555     Document Type: Article

References (16)

1. Lau GKK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. New Engl J Med 2005; 352: 2682-2695.
2. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
3. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-283.
4. Lok A, McMahon B. Chronic hepatitis B: update 2009. HEPATOLOGY 2009; 50: 1-2.
5. Cooksley WGE, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandee T, et al. Peginterferon alfa-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepatitis 2003; 10: 298-305.
6. Piratvisuth T, Lau GKK, Marcellin P, Brunetto M, Kapprell HP, Popescu M. On-treatment decline in serum HBsAg levels predicts sustained immune control and HBsAg clearance 6 months post-treatment in HBeAg-positive hepatitis B virus-infected patients treated with peginterferon alfa-2a [40 kD] (PEGASYS). Hepatol Int 2010; 4: 152.
7. EMEA. ICH Topic E9. Statistical principles for clinical trials. (accessed 25 June 2011).
8. Janssen H, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomized trial. Lancet 2005; 365: 123-129.
9. Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW, Janssen HL. Treatment with peginterferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006; 101: 297-303.
10. Kao JH. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol 2002; 17: 643-650.
11. Wai CT, Chu CJ, Hussain M, Lok AS. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. HEPATOLOGY 2002; 36: 1425-1430.
12. Buster EH, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009; 137: 2002-2009.
13. Bonino F, Marcellin P, Lau GKK, Hadziyannis S, Jin R, Piratvisuth T, et al. Predicting response to peginterferon alfa-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 56: 699-705.
14. Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. HEPATOLOGY 2010; 52: 1251-1257.
15. Piratvisuth T, Marcellin P. Further analysis is required to identify an early stopping rule for peginterferon therapy that is valid for all HBeAg-positive patients. HEPATOLOGY 2011; 53: 1054-1055.
16. Chan HL, Wong VW, Chim AM, Chan HY, Wong GL, Sung JJ. Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. Aliment Pharmacol Ther 2010; 32: 1323-1331.